Report Open Access

Best-practice guidance for the health technology assessment of diagnostics and treatments for COVID-19

Elvidge, Jamie; Summerfield, Ashley; Knies, Saskia; Németh, Bertalan; Kaló, Zoltán; Goettsch, Wim; Dawoud, Dalia


DCAT Export

<?xml version='1.0' encoding='utf-8'?>
<rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:adms="http://www.w3.org/ns/adms#" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dct="http://purl.org/dc/terms/" xmlns:dctype="http://purl.org/dc/dcmitype/" xmlns:dcat="http://www.w3.org/ns/dcat#" xmlns:duv="http://www.w3.org/ns/duv#" xmlns:foaf="http://xmlns.com/foaf/0.1/" xmlns:frapo="http://purl.org/cerif/frapo/" xmlns:geo="http://www.w3.org/2003/01/geo/wgs84_pos#" xmlns:gsp="http://www.opengis.net/ont/geosparql#" xmlns:locn="http://www.w3.org/ns/locn#" xmlns:org="http://www.w3.org/ns/org#" xmlns:owl="http://www.w3.org/2002/07/owl#" xmlns:prov="http://www.w3.org/ns/prov#" xmlns:rdfs="http://www.w3.org/2000/01/rdf-schema#" xmlns:schema="http://schema.org/" xmlns:skos="http://www.w3.org/2004/02/skos/core#" xmlns:vcard="http://www.w3.org/2006/vcard/ns#" xmlns:wdrs="http://www.w3.org/2007/05/powder-s#">
  <rdf:Description rdf:about="https://doi.org/10.5281/zenodo.5530468">
    <dct:identifier rdf:datatype="http://www.w3.org/2001/XMLSchema#anyURI">https://doi.org/10.5281/zenodo.5530468</dct:identifier>
    <foaf:page rdf:resource="https://doi.org/10.5281/zenodo.5530468"/>
    <dct:creator>
      <rdf:Description>
        <rdf:type rdf:resource="http://xmlns.com/foaf/0.1/Agent"/>
        <foaf:name>Elvidge, Jamie</foaf:name>
        <foaf:givenName>Jamie</foaf:givenName>
        <foaf:familyName>Elvidge</foaf:familyName>
        <org:memberOf>
          <foaf:Organization>
            <foaf:name>1. Science Policy and Research Programme, National Institute for Health and Care Excellence (NICE)</foaf:name>
          </foaf:Organization>
        </org:memberOf>
      </rdf:Description>
    </dct:creator>
    <dct:creator>
      <rdf:Description>
        <rdf:type rdf:resource="http://xmlns.com/foaf/0.1/Agent"/>
        <foaf:name>Summerfield, Ashley</foaf:name>
        <foaf:givenName>Ashley</foaf:givenName>
        <foaf:familyName>Summerfield</foaf:familyName>
        <org:memberOf>
          <foaf:Organization>
            <foaf:name>2. Medicines Analysis, NHS England and NHS Improvement, UK</foaf:name>
          </foaf:Organization>
        </org:memberOf>
      </rdf:Description>
    </dct:creator>
    <dct:creator>
      <rdf:Description>
        <rdf:type rdf:resource="http://xmlns.com/foaf/0.1/Agent"/>
        <foaf:name>Knies, Saskia</foaf:name>
        <foaf:givenName>Saskia</foaf:givenName>
        <foaf:familyName>Knies</foaf:familyName>
        <org:memberOf>
          <foaf:Organization>
            <foaf:name>3. National Health Care Institute (Zorginstituut Nederland), Netherlands</foaf:name>
          </foaf:Organization>
        </org:memberOf>
      </rdf:Description>
    </dct:creator>
    <dct:creator>
      <rdf:Description>
        <rdf:type rdf:resource="http://xmlns.com/foaf/0.1/Agent"/>
        <foaf:name>Németh, Bertalan</foaf:name>
        <foaf:givenName>Bertalan</foaf:givenName>
        <foaf:familyName>Németh</foaf:familyName>
        <org:memberOf>
          <foaf:Organization>
            <foaf:name>4. Syreon Institute, Hungary</foaf:name>
          </foaf:Organization>
        </org:memberOf>
      </rdf:Description>
    </dct:creator>
    <dct:creator>
      <rdf:Description>
        <rdf:type rdf:resource="http://xmlns.com/foaf/0.1/Agent"/>
        <foaf:name>Kaló, Zoltán</foaf:name>
        <foaf:givenName>Zoltán</foaf:givenName>
        <foaf:familyName>Kaló</foaf:familyName>
        <org:memberOf>
          <foaf:Organization>
            <foaf:name>4. Syreon Institute, Hungary</foaf:name>
          </foaf:Organization>
        </org:memberOf>
      </rdf:Description>
    </dct:creator>
    <dct:creator>
      <rdf:Description>
        <rdf:type rdf:resource="http://xmlns.com/foaf/0.1/Agent"/>
        <foaf:name>Goettsch, Wim</foaf:name>
        <foaf:givenName>Wim</foaf:givenName>
        <foaf:familyName>Goettsch</foaf:familyName>
        <org:memberOf>
          <foaf:Organization>
            <foaf:name>3. National Health Care Institute (Zorginstituut Nederland), Netherlands,5. Utrecht Centre for Pharmaceutical Policy, Utrecht University, Netherlands</foaf:name>
          </foaf:Organization>
        </org:memberOf>
      </rdf:Description>
    </dct:creator>
    <dct:creator>
      <rdf:Description rdf:about="http://orcid.org/0000-0002-2105-1937">
        <rdf:type rdf:resource="http://xmlns.com/foaf/0.1/Agent"/>
        <dct:identifier rdf:datatype="http://www.w3.org/2001/XMLSchema#string">0000-0002-2105-1937</dct:identifier>
        <foaf:name>Dawoud, Dalia</foaf:name>
        <foaf:givenName>Dalia</foaf:givenName>
        <foaf:familyName>Dawoud</foaf:familyName>
        <org:memberOf>
          <foaf:Organization>
            <foaf:name>1. Science Policy and Research Programme, National Institute for Health and Care Excellence (NICE)</foaf:name>
          </foaf:Organization>
        </org:memberOf>
      </rdf:Description>
    </dct:creator>
    <dct:title>Best-practice guidance for the health technology assessment of diagnostics and treatments for COVID-19</dct:title>
    <dct:publisher>
      <foaf:Agent>
        <foaf:name>Zenodo</foaf:name>
      </foaf:Agent>
    </dct:publisher>
    <dct:issued rdf:datatype="http://www.w3.org/2001/XMLSchema#gYear">2021</dct:issued>
    <dcat:keyword>Health Technology Assessment (HTA)</dcat:keyword>
    <dcat:keyword>COVID-19</dcat:keyword>
    <dcat:keyword>Diagnostics</dcat:keyword>
    <dcat:keyword>Treatments</dcat:keyword>
    <dcat:keyword>Clinical effectiveness</dcat:keyword>
    <dcat:keyword>Cost effectiveness</dcat:keyword>
    <dcat:keyword>Value Framework</dcat:keyword>
    <frapo:isFundedBy rdf:resource="info:eu-repo/grantAgreement/EC/H2020/825162/"/>
    <schema:funder>
      <foaf:Organization>
        <dct:identifier rdf:datatype="http://www.w3.org/2001/XMLSchema#string">10.13039/501100000780</dct:identifier>
        <foaf:name>European Commission</foaf:name>
      </foaf:Organization>
    </schema:funder>
    <dct:issued rdf:datatype="http://www.w3.org/2001/XMLSchema#date">2021-09-27</dct:issued>
    <dct:language rdf:resource="http://publications.europa.eu/resource/authority/language/ENG"/>
    <owl:sameAs rdf:resource="https://zenodo.org/record/5530468"/>
    <adms:identifier>
      <adms:Identifier>
        <skos:notation rdf:datatype="http://www.w3.org/2001/XMLSchema#anyURI">https://zenodo.org/record/5530468</skos:notation>
        <adms:schemeAgency>url</adms:schemeAgency>
      </adms:Identifier>
    </adms:identifier>
    <dct:isVersionOf rdf:resource="https://doi.org/10.5281/zenodo.5530467"/>
    <dct:isPartOf rdf:resource="https://zenodo.org/communities/covid-19"/>
    <dct:description>&lt;p&gt;To support HTA agencies with consistent and pragmatic approaches, we have developed this best-practice guidance for the assessment of technologies for COVID-19. We focused on diagnostic and therapeutic technologies, as the most commonly assessed by HTA agencies. For therapeutics, we focused on treatments rather than post-exposure prophylaxis, however, the recommended approach is unlikely to be much different for prophylactic options.&lt;/p&gt; &lt;p&gt;The recommendations herein are based on findings from a survey and workshop of HTA agencies, a workshop with health economic modellers, and reviews of COVID-19 methods guidance, clinical guidelines, and economic evaluations. They have also been discussed with, and refined with input from, a multi-stakeholder group at a policy sandbox event. The recommendations span several themes relevant to HTA, and some of the key proposals are summarised below. Foremost among them is the recommendation that the pandemic is used as an opportunity to implement a responsive, &amp;ldquo;living&amp;rdquo; approach to HTA.&lt;/p&gt;</dct:description>
    <dct:accessRights rdf:resource="http://publications.europa.eu/resource/authority/access-right/PUBLIC"/>
    <dct:accessRights>
      <dct:RightsStatement rdf:about="info:eu-repo/semantics/openAccess">
        <rdfs:label>Open Access</rdfs:label>
      </dct:RightsStatement>
    </dct:accessRights>
    <dct:license rdf:resource="https://creativecommons.org/licenses/by/4.0/legalcode"/>
    <dcat:distribution>
      <dcat:Distribution>
        <dcat:accessURL rdf:resource="https://doi.org/10.5281/zenodo.5530468"/>
        <dcat:byteSize>1204681</dcat:byteSize>
        <dcat:downloadURL rdf:resource="https://zenodo.org/record/5530468/files/HTx-COVID-Guidance for HTA-Project report-V1.1_For publication.pdf"/>
        <dcat:mediaType>application/pdf</dcat:mediaType>
      </dcat:Distribution>
    </dcat:distribution>
  </rdf:Description>
  <foaf:Project rdf:about="info:eu-repo/grantAgreement/EC/H2020/825162/">
    <dct:identifier rdf:datatype="http://www.w3.org/2001/XMLSchema#string">825162</dct:identifier>
    <dct:title>Next Generation Health Technology Assessment to support patient-centred, societally oriented, real-time decision-making on access and reimbursement for health technologies throughout Europe</dct:title>
    <frapo:isAwardedBy>
      <foaf:Organization>
        <dct:identifier rdf:datatype="http://www.w3.org/2001/XMLSchema#string">10.13039/501100000780</dct:identifier>
        <foaf:name>European Commission</foaf:name>
      </foaf:Organization>
    </frapo:isAwardedBy>
  </foaf:Project>
</rdf:RDF>
954
487
views
downloads
All versions This version
Views 954954
Downloads 487487
Data volume 586.7 MB586.7 MB
Unique views 848848
Unique downloads 433433

Share

Cite as